國藥現代(600420.SH):上半年淨利潤6.72億元,同比下降6.46%
格隆匯7月17日丨國藥現代(600420.SH)公佈2025年半年度業績快報,2025年上半年,公司實現營業收入48.78億元,較去年同期下降18.16%;實現歸屬於上市公司股東的淨利潤6.72億元,較去年同期下降6.46%;實現歸屬於上市公司股東的扣除非經常性損益的淨利潤6.37億元,較去年同期下降6.72%。
報吿期內,受市場供需影響,公司部分青黴素類原料藥及中間體的銷量、價格同比走低;製劑業務板塊,部分頭孢類、激素類、神經類產品受藥品集中採購及終端需求減少等因素影響,銷售收入同比有所下降。面對市場競爭壓力,公司聚焦戰略佈局,積極推進科研開發,加大市場深耕力度,持續推進提質增效、降本控費,期間費用下降明顯,有效穩定了盈利空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.